Elon Musk Embraces Potential of Psychedelics at CodeCon
FeaturedTrending Stories October 1, 2021 MJ Shareholders 0
Enter a long, strange trip into the mind of a genius. Elon Musk—who on September 27 became the world’s richest person, surpassing Jeff Bezos—said people should be “open to psychedelics” at a CodeCon event on Tuesday.
Ronan Levy, executive chairman of Field Trip Health hosted conversation with Musk during an interview at CodeCon 21, a celebrated tech development event, confronting him about whether or not he supports psychedelics for therapeutic purposes.
“I think generally people should be open to psychedelics,” said Musk. The session continued.
“You’ve spent a lot of time talking about outer space, and I want to ask you about inner space. What role do you think psychedelics may have in addressing some of the more destructive tendencies of humanity?” Levy asked Musk.
“A lot of people making laws are kind of from a different era,” Musk replied. “As the new generation gets into political power, I think we will see greater receptivity to the benefits of psychedelics.”
Field Trip Health provides psychedelic-assisted therapies. In an August 31 press release, Field Trip announced new programs, including one that gives eligible therapists the ability to provide ketamine-assisted psychotherapy (KAP) to their patients at Field Trip Health Centers. They will use Field Trip’s medical teams for screening, prescribing and administration of ketamine.
Field Trip’s programs will also provide both didactic and experiential training to therapists and medical professionals on KAP. Therapists who complete Field Trip’s training programs will automatically become eligible to join the KAP Co-op program.
It’s not the first time that the SpaceX founder and multibillionaire has spoken in favor of psychedelics.
On November 14, 2020, Musk tweeted three statements: “You can’t win; You can’t break even; and You can’t stop playing,” then tweeting in the thread, “Unless you’re on DMT.” Twitter couldn’t handle the statement, and commenters guessed whether it was an admission that the billionaire had tried ayahuasca or DMT.
Why is this important? Because so much weight is often put on Musk’s opinions—given his stratospheric wealth and influence. Musk’s powers are evident in the way his comments significantly influenced and tipped the value of Dogecoin and Bitcoin.
Elon Musk on Cannabis
Cannabis—itself a mild psychedelic—is also a recurring theme in the billionaire’s life. In 2019, Musk smoked a blunt on The Joe Rogan Experience—and High Times’ asked if it was “the most expensive blunt of all time?”
Few people in the world are as scrutinized as deeply as Musk when it comes to personal habits like smoking pot. Smoking a blunt live set off a firestorm.
The U.S. Securities and Exchange Commission sanctioned Musk. There was an active petition to get Twitter to deplatform him—and pop stars even dragged him on Instagram. Even Musk’s SpaceX assets were not safe. NASA investigated Musk also, after his debacle on the podcast. According to three unnamed sources who spoke with the Washington Post, NASA launched a safety review of SpaceX shortly after his spot on The Joe Rogan Experience.
Given the level of investments that NASA pours into SpaceX, to them, smoking a blunt was a big deal. At the time, NASA spokesman Bob Jacobs did not comment on whether Musk smoking a blunt was what triggered the review. But he did mention the importance of SpaceX adhering the rules of a drug-free workplace.
On another episode of The Joe Rogan Experience, Musk suggested that most CBD experiences are “fake” and mostly hype. Rogan immediately schooled him, scolding him for dismissing the compound as a benefit for people around the world.
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.